Refining adverse drug reaction signals by incorporating interaction variables identified using emergent pattern mining by Reps, Jenna M. et al.
Reps, Jenna M. and Aickelin, Uwe and Hubbard, 
Richard B. (2016) Refining adverse drug reaction 
signals by incorporating interaction variables identified 
using emergent pattern mining. Computers in Biology 
and Medicine, 69 . pp. 61-70. ISSN 0010-4825 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/34048/1/revision_refinement_edits_nohighlights.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the Creative Commons Attribution Non-commercial No 
Derivatives licence and may be reused according to the conditions of the licence.  For more 
details see: http://creativecommons.org/licenses/by-nc-nd/2.5/
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
Refining adverse drug reaction signals by incorporating
interaction variables identified using emergent pattern
mining
Jenna M. Repsa, Uwe Aickelina, Richard B. Hubbardb
aSchool of Computer Science, Jubilee Campus, University of Nottingham, NG8 1BB
bSchool of Medicine, University of Nottingham, Nottingham, NG5 1PB
Abstract
Purpose: To develop a framework for identifying and incorporating candi-
date confounding interaction terms into a regularised cox regression analysis
to refine adverse drug reaction signals obtained via longitudinal observational
data.
Methods: We considered six drug families that are commonly associated
with myocardial infarction in observational healthcare data, but where the
causal relationship ground truth is known (adverse drug reaction or not). We
applied emergent pattern mining to find itemsets of drugs and medical events
that are associated with the development of myocardial infarction. These
are the candidate confounding interaction terms. We then implemented a
cohort study design using regularised cox regression that incorporated and
accounted for the candidate confounding interaction terms.
Results The methodology was able to account for signals generated due
to confounding and a cox regression with elastic net regularisation correctly
ranked the drug families known to be true adverse drug reactions above those
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that are not. This was not the case without the inclusion of the candidate
confounding interaction terms, where confounding leads to a non-adverse
drug reaction being ranked highest.
Conclusions The methodology is efficient, can identify high-order confound-
ing interactions and does not require expert input to specify outcome specific
confounders, so it can be applied for any outcome of interest to quickly refine
its signals. The proposed method shows excellent potential to overcome some
forms of confounding and therefore reduce the false positive rate for signal
analysis using longitudinal data.
Keywords: Medical Informatics, signal refinement, data mining,
observational data, confounding, emergent pattern mining
1. Introduction
Negative side effects of medication, termed adverse drug reactions (ADRs),
are a serious burden to healthcare ??. ADRs are estimated as the cause of
6.5% of UK hospitalisations ? and a study investigating US death due to
ADRs reported rates between 0.08-0.12 per 100,000 ?. Studies have suggested
that the rate of ADRs is increasing annually ?, motivating the improvement
of methods for detecting them.
The process of detecting ADRs starts during clinical trials, however clini-
cal trials often lack sufficient power to detect all ADRs for numerous reasons
including time limitations, unrealistic conditions and a limited number of
people being included ?. It is then down to post-marketing surveillance to
identify the remaining undiscovered ADRs. This involves three stages: signal
detection (identifying associations between drugs and outcomes), signal re-
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finement (prioritising/filtering spurious relationships) and signal evaluation
(confirming causality after numerous sources of evidence). There has been
a big focus towards developing signal detection methods, involving various
forms of data such as spontaneous reporting systems ?, online data ??, chem-
ical structures ? and longitudinal observational data ??. Unfortunately, all
the data sources have their own limitations. Spontaneous reporting systems
are historically the main source used for post-marketing analysis but often
contain missing values, suffer from under- and over-reporting, and rely on
people noticing ADRs ?. Longitudinal observational data have recently been
used to complement spontaneous reporting system data for extracting new
drug safety information, and are an excellent potential source of information
due to the quantity of observational data available and the number of vari-
ables recorded. If we could overcome existing issues, mainly confounding,
that limit the use of observational data for causal inference then we may be
able to aid the discovery of new ADRs.
We are often plagued with confounding when investigating potential causal
relationships retrospectively in observational data ? due to the data collec-
tion being non-random. When an association between an exposure and out-
come is discovered in observational data, it may often be explained by the
presence of confounding. A confounding variable is one that leads to distorted
effect estimates between an exposure and outcome due to the confounder be-
ing associated with both the exposure and outcome. For a variable to be
considered a confounder of an exposure and outcome relationship it must be
a risk factor of the outcome, it must be associated with the exposure and it
can not lie within the causal pathway between the exposure and outcome.
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Consider, for example, the situation where we wish to determine the
relationship between a drug given to treat hypertension and myocardial in-
farction. If we naively look at the incidence of myocardial infarction within
a year after treatment for patients given the drug and the incidence of my-
ocardial infarction within a randomly chosen year for patients never given
the drug, then we are likely to find that myocardial infarction is more com-
mon in those given the drug and conclude that the drug is associated with
an increased incidence of myocardial infarction. However, our conclusion is
likely explained by confounding, as patients given the drug (those with hy-
pertension) are medically different from those who do not have hypertension.
It is likely that some of the patients given the drug have a poor diet or are
stressed. Poor diet and stress would have contributed to the hypertension
but are also risk factors of myocardial infarction. Therefore poor diet and
stress would be confounding factors. To correctly determine a relationship
between an exposure and outcome it is important to account for confound-
ing variables. Techniques such as risk adjustment, stratification, or equally
distributing the confounding variables between the comparison groups are
potential ways to reduce confounding ?.
Adjusting for confounders in observational data requires identifying the
confounders. Although existing methods aim to address confounding, various
studies have shown that existing signal generation methods developed for lon-
gitudinal observational data have a high false positive rate ??. This is most
likely due to difficulties identifying confounding variables in a data-driven
way. Some studies have shown that including a large number of variables,
such as drug indications, into drug safety methods can reduce confounding
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???, but none of these methods included interactive terms. A medical illness
is likely to be a result of multiple variables interacting. For example, cardio-
vascular disease is common in patients with a genetic predisposition such as
familial hypercholesterolemia and based on lifestyle such as diet and exercise.
Therefore, it is interactive terms between medical events or drugs that are
most likely to correspond to confounding variables. However, when there are
thousands of medical events and drugs, the number of possible interactions is
very large. Existing data-driven methods for incorporating interactive terms
into regression models include hierarchal lasso, which adds the interactions
along with an interaction regularisation term ?, and methods utilising ma-
trix factorisation ?. However, these methods are likely to be highly inefficient
when there are thousands of variables to consider (which is often the case
for observational data). Instead, methods such as emergent pattern mining
? that can efficient identify outcome specific associations, even when large
numbers of variables are being considered, may be more suitable. A simi-
lar idea was used to successfully detect survival associate rules ? based on
cox regression and association rule mining. This shows that it is possible to
reduce confounding by combining cox regression and association rule mining.
A suitable post-marketing framework that extracts knowledge from lon-
gitudinal observational data could be of the form displayed in Figure 1. The
first stage of the proposed framework is to apply an efficient large-scale signal
generation method to find associations between exposures and outcomes. In
the first step the method would efficiently search through all the exposure
and outcome possibilities to find associated pairs. An example of a suit-
able signal generation method is the high dimensionality propensity score
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Figure 1: Overview of the methodology. Our proposed data-driven signal refinement is
applied to ADR signals generated elsewhere to prioritize/filter them before formal evalu-
ation. It will filter some signals that can be explained by confounding and prioritizes the
remaining signals ready for evaluation.
6
(HDPS) ?. The HDPS works by developing a predictive model for taking
the drug and then a matched cohort analysis is applied, where controls are
selected based on having a high propensity for taking the drug (the predic-
tive model predicts that they would have the drug). The HDPS can limit
confounding by accounting for a large number of variables. Unfortunately,
it is not without issues ?? and still often signals many false positives ?, this
highlights the requirement of additional analysis that can reduce the false
positive rate. The second step in the framework is the signal refinement,
where complex confounding relationships are discovered and incorporated
into a more detailed analysis. The output of the signal refinement is a small
set of exposure-outcome pairs that are prioritized for signal evaluation. The
final step would be to formally evaluate the remaining signals using a num-
ber of different data sources, as establishing a causal relationship requires an
accumulation of evidence.
In this paper we focus on the signal refinement stage, as there are no
data-driven methods to refine signals, but numerous signal generation and
evaluation methods exist. The objective of this research is to develop a
data-driven signal refinement methodology that can be applied after ADR
signal generation using longitudinal observational data to filter and re-rank
the signals by addressing complex confounding. We will test the data-driven
methodology by analysing the relationship between numerous drugs and the
outcome myocardial infarction (MI). We are exploring three goals:
1. Whether emergent pattern mining can be used to identify candidate
interaction confounding covariates in a data-driven way.
2. Whether the inclusion of interaction confounding covariates into a re-
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gression analysis can reduce confounding and be used for data-driven
ADR signal refinement.
3. Whether lasso and ridge regularisation are suitable techniques to enable
the inclusion of a large number of potential interaction covariates.
2. Materials and Methods
2.1. Materials
The longitudinal observational database used in this study is The Health
Improvement Network (THIN) database (www.thin-uk.com). THIN contains
complete medical records for patients registered at a participating general
practice within the UK. At present approximately 6% of the UK general
practices are participating, resulting in THIN containing data on over 4 mil-
lion active patients. The validity of the THIN database for pharmacoepi-
demiology studies has been investigated ? and it was shown that the data
appear to be representative of the UK population.
THIN contains time-stamped entries of drugs that are prescribed and
medical events that the general practices are made aware of. Prescribed drugs
are recorded with a British National Formulary (BNF) code indicating the
family of the drug prescribed. Medical events are recorded using the Read
coding system. The Read codes used in this study to identify myocardial
infarction (MI) are available in Supplement A.
The drug families (represented by BNF codes) investigated in this study
are presented in Table 1 along with the ground truth (the known relationship
between each drug family and MI), the number of prescriptions eligible for
inclusion in the study and number of MI that occurred after an eligible
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prescription of each BNF. The ground truth relationship between these BNFs
and MI are as specified in the Health Outcome of Interest (HOI) reference
set used by the Observational Medical Outcomes Partnership (OMOP) ?.
Table 1: Summary of number of patients prescribed each drug family and number of
patients who experience MI within 5 years of their first time prescription.
Drug Family BNF+ No. First time
prescriptions
No. of MI*
after BNF
MI is a known
ADR?
Typical antipsy-
chotics
04020100 10061 44 Yes
Benzodiazepines 04010200 74582 277 No
Tricyclic antide-
pressants
04030100 61384 221 Yes
Antibiotics 1 05010300 78296 247 No
Antibiotics 2 05010800 91515 258 No
Bisphosphonates 06060200 8967 67 No
Note: + BNF: British National Formula, * MI: Myocardial Infarction
2.2. Analysis Methods
2.2.1. Emergent Pattern Mining
Emergent pattern mining is a type of association rule mining that aims
to find differences between databases. Formally, let I = {i1, i2, , in} be the
set of n items and t =⊂ X be a transaction containing a set of items. A
database is a collection of transactions, denoted by D = {t1, t2, , tm}. The
support of an itemset X in database D is the proportion of the database
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transactions that contain X,
SuppD(X) = |{ti ∈ D|X ⊂ ti}|/|D| (1)
where |D| is the number of transaction in the database. An itemset is fre-
quent if it has a support greater than some user defined minimum support
value.
In the drug safety context, I represents the observational databases clin-
ical vocabulary (e.g., International Classification of Diseases and RxNorm),
and a patients transaction may correspond to the set of codes that they have
recorded in the database during a specified time interval. An itemset is a
collection of clinical vocabulary codes (e.g., {drug1, illness350, drug924}),
and the support of the itemset is the fraction of the database’s patient trans-
actions that contain the itemset.
The idea of emergent pattern mining is to find itemsets that have a higher
support in one database than others ?. A simple method for determining the
emergent patterns is to find the itemsets that have a sufficiently high support
in one of the databases and then calculate the lift,
lift(X) = SuppD1(X)/SuppD2(X) (2)
However, this measure is vulnerable to volatility due to small support
values and a bias-adjusted lift may be more suitable,
biaslift(X) = (SuppD1(X) + 1)/(SuppD2(X) + 1) (3)
this measure adds a bias towards 1 when the support is low and is a common
approach for dealing with rare events in drug safety[28].
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2.2.1.1 Cox Regression
Cox regression was chosen as this enables the consideration of the time to
event (enabling long term effects to be evaluated) and the inclusion of right-
censored data. Using a method that ignores the time-to-event, such as logistic
regression, would likely result in bias, as patients who leave the practice or
die from alternative illnesses (right-censored patients) would not be included
into the analysis ?. The cox regression model assumes that the hazard at
time t given the covariates x and baseline hazard is,
h(t|x) = h0(t)exp(
∑
j
xjβj) (4)
The parameter β is determined by maximising the partial likelihood ?.
2.2.1.2 Regularised Cox Regression
Regularisation is a technique to prevent models overfitting by adding a con-
straint to the complexity of the model. This is necessary when there are
too many covariates in the model. In terms of cox regression, regularisation
techniques add a constraint to the total size of the coefficients in the model.
There are two main forms of regularisation penalty functions, ridge ? and
lasso ?. The elastic net regularisation combines both the lasso and ridge
penalty functions ?. Lasso regression is a regularised regression that adds
a constraint to the total sum of the absolute value of the model coefficients
into the optimisation,
λ||β||1 = λ
∑
j
|βj| (5)
This effectively causes some of the coefficients to disappear and is useful
when there are a smaller number of medium or large effects. It has problems
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when there are correlations between covariates, as it will only pick one of the
correlated covariates coefficients to be non-zero. Lasso regression has been
used successfully with the aim of overcoming confounding in drug safety ?
but no existing approach has included interactive terms.
Ridge regression adds a constraint to the sum of the coefficients squared
into the optimisation,
λ||β||2 = λ
∑
j
β2j (6)
this causes all the coefficients to shrink to zero as lambda tends to infinity.
Ridge regression is useful if there are small effects, which may be the case
for ADRs. Finally, the elastic net linearly combines both ridge and lasso
regression penalties,
λ1||β||1 + λ2||β||2 = λ1
∑
j
|βj|+ λ2
∑
j
β2j (7)
using the parameter α ∈ [0, 1] = λ1/(λ1 + λ2).
The regularised cox regression can be used to indicate the relative im-
portance of each variable in determining the time-to-event of MI. If the drug
suspected of causing MI is deemed to have a large coefficient by the reg-
ularised cox regression then this strengthens our suspicion, especially when
alternative risk factors for developing MI are accounted for within the model.
2.3. Method
The proposed signal refinement methodology has two steps. Step 1 in-
volves applying emergent pattern mining to identify sets of medical conditions
and medication that are risk factors for developing the outcome (candidate
positive confounder interactions) or factors that reduce the likelihood of de-
veloping the outcome (candidate negative confounder interactions). Step 2
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involves implementing a cohort study design and a risk adjusted multivariate
analysis (e.g. regularised cox regression) with risk adjustment terms account-
ing for the candidate confounder variables identified in step 1.
2.3.1. Step 1 Candidate interactive confounder identification
2.3.1.1 Select Data
We imitated the data extraction of a case control study design to extract
data for the emergent pattern mining. In this step we did not apply a case
control design to investigate the effect of exposure, we just extracted the
case control study design data for the emergent pattern mining. The cases
are the patients who have the outcome recorded; their index date is the first
time the outcome is recorded. Then two controls are selected for each case
by matching on age (plus or minus 1 year), gender and general practice and
finding the two patients that have the closest registration date to the case.
We chose to match two controls per case as the majority of cases had two
potential matches and the greater the number of controls, the more likely
each itemsets support value will approximate the actual prevalence. Each
control’s index date is the date of their matching cases index date. The
exclusion criteria are: patients with a history of any of the exposures being
investigated prior to index were excluded. Controls must have zero recordings
of the outcome in the data. The inclusion criteria are: patients that are aged
between 18 and 70 and patients must have been registered for at least a year
prior to their index date. Figure 2 illustrates the implemented case control
style design for extracting suitable data to apply emergent pattern mining
to. The emergent pattern mining will find sets of drugs/medical conditions
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Table 2: Example of transactions found in D1 (the patients with the outcome recorded in
the database)
Patient
ID
Index Date
(date of
outcome)
General
Practice
Sex Date of
Birth
Medical transactions*
1 01-02-2008 2 M 02-07-1967 Drug1, Drug110, Ill-
ness1020, Illness15001
15 23-01-2001 20 M 16-04-1936 Drug204,Drug110,Illness1020,
llness3
37 12-12-2001 1 F 03-12-1942 Illness4
... ... ... ... ... ...
Note: * - All recorded prescriptions/medical items prior to index date
that occur more often prior to index for the cases (those with the outcome,
in our example MI) compared to the controls. These correspond to potential
risk factors for the outcome.
2.3.1.2 Create patients transaction baskets
We then create two databases D1 and D2, see Tables 2-3. D1 contains the
case patients medical transactions, i.e. the set of all medical events or drugs
recorded prior to the index date for each patient in the case control study. D2
contains the control patients medical transactions, i.e. the set of all medical
conditions or drugs recorded prior to the index date.
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Year
1995 2005 2010 2015
Included?
Case index date
is first recording
of outcome (e.g. MI)
3 Case Patient 1 ♀
Control index date
matches case’s
index date
3Control
Patient1
Patient 2 ♀
3Control
Patientn
Patient 3 ♂
3Control
Patientn
Patient 4 ♂
Inclusion or Exclusion
criteria not met
7 Short
history Patient 5 ♂
7 Patient 6 ♀
7 Patient 7 ♂Exposurehistory
7 Patient 8 ♂
Records prior to
index extracted for
included patients
3Control
Patient32
Patient 9 ♀
7 Patient 10 ♂
...
3 Case Patient n ♂
Index
Key
- outcome of interest
- exposure 1 of interest
- exposure 2 of interest
...
- exposure n of interest
Figure 2: Step 1 study design illustration: For each patient in the longitudinal ob-
servational database we have their prescription timeline (dashed lines) and condi-
tion/observation timeline (straight line) since registration until they leave the practice
or die. Circles represent recorded conditions and rectangles represent recorded medica-
tion. Each colour of the shape represents a type of drug or condition, for example a red
rectangle represents MI. The patient’s timeline colour corresponds to their general prac-
tice. The index date used for step 1, the first outcome record date, is represented by a
dotted line.
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Table 3: Example of transactions found in D2 (the controls matched on practice, gender
and age)
Patient
ID
Index Date General
Practice
Sex Date of
Birth
Medical transactions*
1020 01-02-2008 2 M 23-09-1967 Drug1, illness43, Ill-
ness2, Drug203
1031 01-02-2008 2 M 01-05-1968 Illness3
43 23-01-2001 20 M 08-02-1936 Illness3, Illness4010
... ... ... ... ... ...
Note: * - All recorded prescriptions/medical items prior to index date
2.3.1.3 Identify emergent patterns
We then apply frequent itemset mining to D1 with a minimum support of
0.001 to find all the cases’ frequent itemsets ID1 and apply frequent itemset
mining to D2 with a minimum support of 0.0005 to find all the controls’
frequent itemsets ID2. The positive measure of interestingness is calculated
by dividing the support of each itemset, X ∈ ID1, by its support in D2 but
we add a bias to reduce the measure to one for small support values. For
each X ∈ ID1 we calculate,
biasliftD1D2(X) =

( SuppD1(X)+1)
(SuppD2(X)+1)
if X ∈ ID1 ∩ ID2
(SuppD1(X) + 1) if X ∈ ID1, X 6∈ ID2
0 otherwise
(8)
The candidate positive confounding variables are the {X ∈ ID1|biasliftD1D2(X) >
1}. The negative emergent patterns are found in a similar manner but we
apply frequent itemset mining to D2 with a minimum support of 0.001 to
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find all the controls frequent itemsets ID2 and apply frequent itemset min-
ing to D1 with a minimum support of 0.0005 to find all the cases frequent
itemsets ID1. We then calculate biaslift
D2
D1(X) and determine the candidate
negative confounding variables as {X ∈ ID2|biasliftD2D1(X) > 1}.
For example, if we found that the itemset {Drug110, Illness1020} had a
support of 0.05 in D1 (the itemset is found in the medical transactions for
every 5 out of 100 patients with MI) and a support of 0.005 in D2 (the itemset
is found in the medical transactions for every 5 out of 1000 control patients).
Then biaslistD1D2({Drug110,Illness1020}) = 1.05/1.005 = 1.045 and would be
considered a candidate positive confounding variable.
The minimum support value was a trade off between finding as many
itemsets as possible and finding useful itemsets. The minimum support of
0.001 means any identified itemset would be found in a minimum of 1 in 1000
patients with MI. A support value less than 0.001 would likely find irrelevant
itemsets, as they would be too rare to be useful. The support was reduced
for the comparison database to increase the chance that the itemset is found
in both databases frequent itemsets.
Although it is possible to identify itemsets of any size using frequent
itemset mining, in this paper we added a constraint to only find itemsets
containing 5 items or less. This ensured the method was highly efficient and in
general we found that itemsets containing more than 5 items often had small
support values, so this constraint is unlikely to affect the results. Overall
we were efficiently able to identify interactions containing up to 5 variables
that are associated with developing MI. We found 23808 variables recorded
into THIN for patients who had MI recorded, this means we searched through
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Table 4: Example of the results of the emergent pattern mining. The most suitable
variables are selected based on them having the greatest biaslift value.
Itemset D1 Support D2 Support biasliftD1D2 biaslift
D2
D1
{Drug110,Illness1020} 0.05 0.005 1.045 0.957
{Illness3, Illness4010} ¡0.0005 0.001 - 1.001
{Drug201, Drug 104,
Illness1023}
0.0012 ¡0.0005 1.0012 -
... ... ... ... ...
6.35×1014 , ∑( k = 2)5(23808k ), possible interactions to find the most common
ones that are associated with developing myocardial infarction.
2.3.1.4 Select emergent patterns
Table 4 displays the results of the emergent pattern mining approach (a list
of sets of medical items that occur more for patients with/without the out-
come). Finally we select the top k candidate positive confounding variable
itemsets (with the greatest biasliftD1D2) and the top k negative confounding
variable itemsets (with the greatest biasliftD2D1). These will be included into
the cox regression using indicator variables to mark their presence or absence
in each cohort patients medical history prior to their cohort index date. In
this study we chose k = 200 as this seemed to give a sufficient number of can-
didate confounders while still enabling the methodology to be implemented
efficiently.
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2.3.1.5 Justification
The motivation for applying a case control study combined with emergent
pattern mining is that we can find illnesses/drugs that are more common in
the patients who have the exposure compared to those who never develop
the exposure. These are the potential risk factors for the exposure, the first
criterion necessary for a variable to be a confounder to the exposure- outcome
relationship. By excluding patients from the case control data extraction who
have the exposures being analysed, we are preventing the discovery of risk
factors that are within the causal pathway between exposure and outcome
(as this would violate the third criterion necessary for a variable to be a
confounder).
2.3.2. Step 2 Cohort study with risk adjusted multivariate analysis
2.3.2.1 Select Data
We implement a cohort study design with a 5-year follow up period. For each
drug family of interest being investigated, we find all the patients prescribed
the drug family for the first time between the years 2005 and 2010 and
set their index date as the first time prescription of the drug family. The
inclusion criteria are: patients are aged between 18 and 65 at index (because
we use a 5 year follow up and the emergent patter mining was for patients
aged 70 or younger) that have more than 1 years history prior to the index
date. Figure 3 illustrates the study design implemented in step 2, where each
shade of blue circle corresponds to one of the exposures being investigated.
If a patient was prescribed more than one of the exposures being investigated
for the first time during 2005 and 2010, then they would be included multiple
19
Table 5: Example of the results of the emergent pattern mining. The most suitable
variables are selected based on them having the greatest biaslift value.
Patient Age Sex Exposure1
(06060200)
... ExposureN
(04010200)
Itemset1 ... Itemset400 Outcome
2032 64 M 1 ... 1 0 ... 1 1
10570 49 F 0 ... 0 0 ... 0 0
34 58 M 1 ... 1 0 ... 0 1
... ... ... ... ... ... ... ... ... ...
times into the cohort but with different index dates, see patient 8 in Figure
3.
The covariates used in the cox regression model are the patients age/gender,
indicator variables for each of the drug families being investigated (1 if the
patient had a prescription of the drug family recorded prior to or on the index
date and 0 otherwise) and indicator variables for each of the 400 candidate
confounder itemsets identified in step 1 (1 if the patient has all items in the
itemset recorded prior to index date and 0 otherwise). An example of the
data used to learn the cox regression model is displayed in Table 5.
2.3.2.2 Cox Regression Models
We then implement various regularised cox regression models (using the elas-
tic net regularisation detailed in equation 7 with various α ∈ [0, 1] values
including lasso:α = 1 and ridge:α = 0) using age/sex, drug family history
indicators and candidate interaction confounders covariates. For compari-
son we also implement a standard cox regression model that only used the
20
Year
1995 2005 2010 2015
Find first time
exposures
Included?
7 Patient 1 ♀
3
Index is date of
first time exposure
during 2005-2010
Time-to-event
based on outcome
occurring during
follow-up
Patient 2 ♀
7 Patient 3 ♂
7 Patient 4 ♂
7 Patient 5 ♂
7 Patient 6 ♀
3
Exposure of interest
are represented
as blue circles
Patient 7 ♂
3 3 Patient 8 ♂
Use presence of risk
factors prior to
index as covariates
7 Patient 9 ♀
7 Patient 10 ♂
...
7 Patient n ♂
Key
- outcome of interest
- exposure 1 of interest
- exposure 2 of interest
...
- exposure n of interest
Figure 3: Step 2 study design illustration: For each patient in the longitudinal ob-
servational database we have their prescription timeline (dashed lines) and condi-
tion/observation timeline (straight line) since registration until they leave the practice
or die. Circles represent recorded conditions and rectangles represent recorded medica-
tion. Each colour of the shape represents a type of drug or condition, for example a red
rectangle represents MI and the different shades of blue circles represents the different
exposures of interest. The patient’s timeline colour corresponds to their general practice
and their gender is represented by gender symbols.
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age/sex and drug family indicator covariates.
2.3.2.3 Validation
Following standard computer science methodology we split the data into
test/train sets. 50% of the data were used to train the cox regression models,
as this was ample, and the remaining 50% of the data were used to validate
the models. The summary time-dependant area under the receiver operating
characteristic curve (AUC) ? was calculated to validate the model fit.
2.3.2.4 Software
The data were stored and manipulated in MS SQL Server and the analysis
was conducted using the open source analysis language R ?. The frequent
pattern mining was implemented using the arules package’s Apriori algorithm
?, the standard cox regression was implemented using the survival package
?, the regularised cox regression was implemented using the glmnet package
? and the model validation was implemented using the survAUC package.
3. Results
3.1. Emergent pattern mining results
We identified 77, 246 eligible patients who had MI recorded and these
patients transactions were included into D1. We matched 150, 304 patients
into D2. The frequent pattern mining was applied to 23, 808 items in D1
and found 3, 886, 408 frequent itemsets for D1 with a minimum support of
0.001 (9920792 with a minimum support 0.0005). For D2 there were 26, 705
items, with association rule mining identifying 2, 092, 949 frequent itemsets
22
for D2 with a minimum support of 0.001 (5, 502, 600 with a minimum sup-
port 0.0005). In total we identified 3, 838, 643 potential candidate positive
confounders and 57, 507 potential negative confounders, however only the top
200 positive and top 200 negative candidate confounders were selected.
One interesting observation of the emergent pattern mining results is that
the there were more frequent itemsets discovered for the patients with MI
compared to the control group in step 1. One explanation of this is that
patients with MI are likely to be similar and share the common risk factors
or MI preceding events, so the D1 dataset will be less sparse compared to D2,
which consists of a more varied population. Another reason D2 is sparser is
that it contained healthier (non-MI) patients, some of which may not have
many items recorded. In future work it would be interesting to restrict D2
to patients with certain criteria, such as having a minimum number of items,
and investigating how this effects the emergent patterns that are discovered.
3.2. Cox regression results
In total we used data for 162, 889 patients for the cox regression analysis.
The model concordance for the standard cox regression was 0.82 and none of
the covariates violated the proportional hazard assumption. Table 6 presents
the ranking of the drug families based on the coefficient values obtained
from a cox regression that only used the age/sex and drug family indicator
covariates. The non-ADR bisphosphonates (BNF 06060200) was found to
have the greatest hazard ratio.
Table 7 presents the results of the elastic net regularised cox regression
with the 6 drug families, age/sex and 400 candidate interactive confounders
as covariates. The two known ADRs were correctly ranked above the non-
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Table 6: Results of cox regression that does not include the candidate confounding inter-
action variables.
Rank Drug Family
Covariate
Coefficient Hazard Ratio (95% CI) Truth
1 06060200 0.563 1.757 (1.326-2.326) Non-ADR
2 04020100 0.398 1.488 (1.103-2.009) ADR
3 04030100 0.255 1.291 (1.086-1.534) ADR
4 05010300 0.150 1.162 (0.977-1.382) Non-ADR
5 05010800 0.136 1.145 (0.958-1.369) Non-ADR
6 04010200 0.069 1.071 (0.896-1.280) Non-ADR
ADRs when candidate confounders were incorporated via a ridge cox regres-
sion.
On the 50% testing data the time dependant AUC for the standard cox
regression was 0.816, the lasso regularised cox regression obtained an AUC
of 0.825 and the ridge regularised cox regression obtained an AUC of 0.785,
indicating strong model fits.
4. Discussion
This is the first methodology proposed for incorporating candidate in-
teraction confounder covariates into a cox regression for drug safety. The
standard cox regression that only considered indication of the various drug
families on the day of or prior to index, age and sex ranked bisphospho-
nates (BNF 06060200), a non-ADR, as the most likely to cause MI. How-
ever, incorporating the candidate interaction confounders into the elastic net
regression with small values for α reduced the confounding in the analysis
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Table 7: The results of the elastic net cox regression. No. βs is the number of variables
selected by the model.
Parameters
α 1 (Lasso) 0.6 0.3 0.1 0.05 0 (Ridge)
λ* 3.7×10−4 1.4×10−4 3.3×10−4 8.3×10−4 1.4×10−3 8.1×10−3
No. βs 6 26 30 51 73 266
—
Covariate Coefficient values β (Rank) Truth
04030100 0 0.030
(17)
0.006
(23)
0.011
(33)
0.0123
(38)
0.0112
(64)
ADR
04020100 0 0 0 0.003
(38)
0.011
(41)
0.011
(67)
ADR
06060200 0 0.12 (6) 0.0152
(21)
0.012
(30)
0.0120
(39)
0.009
(80)
Non-
ADR
05010300 0 0 0 0 0 0.008
(84)
Non-
ADR
04010200 0 0 0 0 0 −7×10−4
(166)
Non-
ADR
05010800 0 0 0 -0.006
(42)
-0.022
(66)
-0.018
(262)
Non-
ADR
Note:
-λ* is the maximum lambda that was within 1 standard deviation of the minimal
cross-validation error as this was a trade off between maximising regularisation
and minimising error.
- Bold entries correspond to the top ranked drug family
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and correctly ranked the two known ADRs, tricyclic antidepressants (BNF
04030100) and typical antipsychotics (BNF 04020100), above bisphospho-
nates. As α increased from 0 in the elastic net regression, the framework
was unable to reduce the confounding completely and still incorrectly ranked
bisphosphonates as the most likely cause of MI. As α increased towards 1
(lasso regression), it was generally observed that the regularised regression
did not identify any of the drug families as causes of MI, however, at certain
small values of α (e.g., α = 0.1 ,α = 0.05), the lasso effect nicely filters
some of the non-MI causing drug families, although bisphosphonates were
still ranked above some of the known ADRs. This shows that elastic net cox
regression including the candidate interactive confounders has the potential
to not only re-rank ADRs signals, but also filter the false positive signals.
The results suggest the ideal ADR signal refinement framework should take
a multiple step approach and combine results obtained with various values of
α. For example, use elastic net cox regression with a small α to filter signals
firstly and then use elastic net cox regression with α set to zero to rank the
remaining signals.
One possible reason why the elastic net cox regression with α = 0 was
able to correctly rank the drug families is that it incorporated more covari-
ates into the model, even those with small effects. The result that the elastic
net cox regression with a small α was better than lasso regression, also pro-
vides some evidence that the candidate interactive confounder covariates are
appropriate, as including them into the cox regression reduced confounding.
The fact that lasso regression shrunk all the drug families coefficients to zero
is not unexpected, as lasso regression identifies large/medium effects, but
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ADRs that are difficult to distinguish from confounding are likely to have
a small effect size. This suggests that the choice of α will depend on the
outcome being investigated (e.g., is it common/rare) and the relationship
between the drugs and outcome. Rather than relying on the results obtained
by picking the optimal lambda for lasso regression, it may be suitable to
investigate the results returned for a range of lambdas and identify the order
in which the drug family variables are entered into the regularised models as
the regularisation decreases. The last n occurring drug family variables (or
those with negative coefficients) could then be filtered out. Another possible
explanation for elastic net cox regression with α = 0 outperforming lasso is
due to unmeasured confounding. If there are many unmeasured confounders,
then adding more candidate interaction confounder covariates may increase
the chance of identifying a proxy variable for some unmeasured confounding.
Therefore, as elastic net cox regression with a small α includes more covari-
ates it will have an advantage over lasso regression, as it is may overcome
some unmeasured confounding.
We purposely chose MI in this study as the outcome of interest due to
it having a high background rate, so confounding is a common issue, and
also due to missing data problems being common (MI may only be recorded
in secondary care and missed from the primary care record). For example,
some patients experiencing a MI may not have the event recorded in their
primary care records as they may go to hospital. Hospitalisation may also
cause the recording date to be incorrect in THIN. By purposely choosing
a difficult outcome, we are testing whether the proposed method can over-
come both confounding and data recording issues. However, the proposed
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method does require that the patients have medical histories; otherwise it
would not be possible to identify confounders related to outcome progres-
sion. This may limit which databases the methodology can be applied to,
as longitudinal observational data with short observation periods are less
suitable, although even a short period of history may be useful for reducing
confounding. Therefore, it would be useful in future research to determine
whether the proposed method can successfully reduce confounding when ap-
plied to other outcomes or when implemented for signal refinement using
other longitudinal observational data.
Overall the methodology shows promise at refining ADRs by reducing
confounding. The results show that combining emergent pattern mining and
elastic net cox regression is an effective and efficient data-driven framework
for reducing the issue of confounding that is common in longitudinal obser-
vational studies. However, further research is required to identify:
• The optimal value for k (the number of candidate confounder covari-
ates)
• The most suitable choice of α for the elastic net (or combination)
• The types of outcomes that are suitable for the method (e.g., common,
rare, progressive, chronic, acute)
The proposed methodology has the advantage of being efficient as it is data-
driven, it is applicable for analysing both short-term and long-term ADRs
and it can remove false ADR signals. However, formal epidemiology study
designs will still need to be applied to the unfiltered signals before causality
can be established.
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5. Conclusions
In this paper we proposed a novel framework to efficiently enable the in-
clusion of high-order interactive terms, potentially representing confounders,
into a cox regression analysis to refine ADR signals. The framework com-
bines emergent pattern mining, that searches billions of possible interactions
to identify terms potentially corresponding to confounders, and regularised
cox regression. We investigated the framework by applying it to investigate
how likely six different drug families are to cause MI. The drug families were
chosen as they are from a reference set developed to evaluate ADR signal
detection methods and there have been numerous studies investigating their
relationships with MI. A standard cox regression only considering the risk
adjustments of age, sex and indicators for the five drug families was shown
to be negatively effected by confounding. However, our proposed automated
framework for incorporating candidate confounder interaction terms into an
elastic net cox regression was shown to be more resilient to confounding and
correctly ranked the drug families in order of how likely they are to cause
MI. This shows excellent potential for reducing the current high false positive
rate issue when using longitudinal observational data for drug safety.
In future work the framework’s robustness should be tested by imple-
menting the framework to refine ADR signals for alternative outcomes or by
using alternative longitudinal observational data.
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